Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Abstract The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer’s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Alexander C. Conley, Alexandra P. Key, Jennifer U. Blackford, Jason K. Russell, Kimberly M. Albert, Xuewen Gong, Michael Bubser, Jerri M. Rook, P. Jeffrey Conn, Craig W. Lindsley, Carrie K. Jones, Paul A. Newhouse
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2025-07-01
Rangatū:	Alzheimer’s Research & Therapy
Ngā marau:	Muscarinic acetylcholine receptor subtype 1 (M1) Positive allosteric modulator (PAM) Cognition Metabolism Pharmacokinetics Pharmacodynamics
Urunga tuihono:	https://doi.org/10.1186/s13195-025-01798-4
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!